Skip to main content
EVMN logo

EVMN · Evommune, Inc.

Track EVMN — free
$7.04 -0.20 (-2.76%) At close · Nov 20
Market Cap
$291.10M
Shares
41.35M
Volume · Nov 20 549.4K Avg daily vol (3M) 834K

Price & Indicators

 

Key stats

Close
$7.04
Fri 20 Nov
Open
$7.10
Fri 20 Nov
Average volume, 30 days
863K
shares a session
Short interest
3.4M
8.2% of shares · 3.0 days to cover
Day range
$6.96$7.24
Open $7.10 Close $7.04
52-week closing range
$5.10$31.57
Close $7.04 77.7% under the high
Short volume, last session
61%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 12
Price history
Nov 2025 to Nov 2026

Latest documents

2026
Nov 18
Investor event
$290 million cash funds readouts through second half of 29

Evommune reports $290 million in cash, funding its pipeline through the second half of 29. Its 330-patient oral migraine trial reads out in the second half of 2027.

2 source passages
we have $290 million in cash that take us through the second half of 29. This is currently enrolling in a robust 330-patient migraine trial, and that study is going to read out in the second half of 2027. Open the document at this passage
Nov 17
Current report 8-K Events of Nov 13
Approves option repricing to $7.63 and executive cash retention awards

Evommune approved cash retention awards for its Chief Executive Officer, Chief Financial Officer, and Chief Business & Legal Officer, and repriced underwater stock options to $7.63 per share, covering 3,692,840 shares.

Director or officer change, or executive pay
4 source passages
the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Evommune, Inc. (the “Company”) approved the entry of an amendment to the applicable employment agreement(s) with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer the exercise price per share for such Eligible Option was reduced to $7.63, the closing price of the Company’s common stock as of the November 13, 2026 The total number of shares underlying all Eligible Options is 3,692,840 shares. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
EVO756 discontinued in CSU and AD; runway reaches 2029

Evommune discontinued EVO756 development in CSU and AD after Phase 2b trials missed endpoints, while migraine development continues. It reported $262.3 million in liquidity and expects funding into the second half of 2029.

Revenue $0 Net loss $30.88M Diluted EPS -$0.85
Read from the MD&A section
5 source passages
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on atopic dermatitis (“AD”), migraine and ulcerative colitis (“UC”). In June 2026, we announced top-line results from our randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial evaluating EVO756 in adults with moderate-to-severe CSU. The trial did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose, and based on these results, we have decided to cease development of EVO756 for CSU. In September 2026, we announced top-line results from our randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial evaluating EVO756 in adults with moderate-to-severe AD. The trial did not meet the primary endpoint in any of the doses studied, and based on these results, we have decided to cease development of EVO756 for AD. We are continuing to evaluate EVO756 in migraine and have initiated a Phase 2b trial of EVO756 in migraine prophylaxis in July 2026. As of September 30, 2026, we maintained $262.3 million in cash, cash equivalents and investments. We expect that our cash, cash equivalents, and investments as of September 30, 2026, together with the proceeds we received from the Private Placement, will enable us to fund our operating expenses and capital expenditures requirements into the second half of 2029, based on our current business plan. Open the document at this passage
Nov 12
Current report 8-K
EVO570 licensing accompanies $30 million private placement

Evommune licensed EVO570 from Hinova for $30 million upfront and raised approximately $30 million through a private placement, reporting $262.3 million in cash, cash equivalents and investments and cash runway into 2H 2029.

Financial results, Regulation FD disclosure
4 source passages
In November 2026, Evommune entered into an exclusive license agreement with Hinova granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118). Evommune paid $30 million upfront, consisting of $20 million in cash and $10 million in the form of pre-funded warrants to purchase Evommune common stock. In November 2026, concurrent with the in-licensing of EVO570, Evommune entered into a securities purchase agreement to sell 4,966,889 shares of its common stock at $6.04 per share to a select group of dedicated healthcare institutional investors, for gross proceeds of approximately $30 million. Strong balance sheet with cash runway into 2H 2029 to deliver multiple key milestones across the pipeline Cash, Cash Equivalents and Investments: As of September 30, 2026, the Company had cash, cash equivalents and investments of $262.3 million, compared to $216.7 million as of December 31, 2025. Open the document at this passage
Nov 5
Current report 8-K
Webcast to Detail EVO570 Development and License Terms

Evommune made a pre-recorded webcast available at 8:30 a.m. ET on November 5, 2026, covering EVO570’s preclinical profile, planned rheumatoid arthritis development path and Hinova Pharmaceuticals Inc. license terms.

Regulation FD disclosure
3 source passages
The webcast will be available at 8:30 a.m. ET on Thursday, November 5, 2026, on the News & Events page of the Company’s website at An archived replay will remain on the website for 30 days following the event. Management will cover the biology of VAV1, EVO570’s preclinical profile, the planned development path in rheumatoid arthritis, the terms of the transaction and how EVO570 fits within the Company’s broader immunology pipeline. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD). Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$113.07M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.6
Trailing earnings · reciprocal yield 181.1%
FCF yield
-31.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$168.30M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,251.2%
Year over year · more shares
Price change (1Y)
-62.4%
Trailing year
Short interest
8.2%
Latest settlement · 3.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −58%
below
Price vs 50-day avg −1%
below
RSI (14) 50
neutral
MACD trend Positive
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +38%
trailing
6-month return −64%
trailing
YTD return −59%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $17 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.19% of shares out · ▼ -4.1% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
104 holders — near 1-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth +86%
Y/Y
EPS growth +75%
Y/Y
Free cash flow $-76.7M
Balance sheet $43.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 120%
annualized · 1-yr
Max drawdown −84%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−58% Bearish
Price vs 50-day avg
−1% Neutral
RSI (14)
50 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $17 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.19% of shares out · ▼ -4.1% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
104 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $7 · 7% Range high $32
vs 200-day avg -58% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
least-squares mean reduction from baseline in Eczema Area and Severity Index (EASI) 55% Week 12 —
patients achieved vIGA 0/1 23% week 12 —
patients achieved vIGA 0/1 on placebo 0% week 12 —
placebo-adjusted EASI improvement 34% week 8 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVMN
Evommune, Inc.
this stock
$291.10M -58.9% +85.7% — 8.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
104
% held
81.0%
Net QoQ
-1.1M sh
Top holder
EQT Fund Management S.a r…
Held Float
View
Held by Funds
Fund positions
120
View
Short & Settlement
Short Interest Falling
Shares short
3.4M
Days to cover
3.0d
Change
-146.4K sh
View
Short Volume
Short vol %
61%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
7.6K
Value
$52.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
38.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$13.0M
Net income (FY)
$-68.9M
EPS diluted
$-11.22
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
28

Evommune reports $290 million in cash, funding its pipeline through the second half of 29. Its 330-patient oral migraine trial reads out in the second half of 2027.

View
Proposed Sales
Value
$427.2K
Shares
20.0K
Filed
Jun 22, 2026
View
Exempt Offerings
Offering
$57.5M
Filed
Jan 8, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Evommune Reports Third Quarter 20…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
EVMN -7.7% +38.0% -64.5% +4.6% -58.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.8% +47.3% -55.3% +13.3% -60.0%
Key facts CIK 2044725 CUSIP 30054Y107 13F (30d) 99 filings 97 filers Visit website Investor relations